Medpace Stock Forecast, Price & News

Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medpace wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Medpace?

Medpace saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 879,900 shares, an increase of 19.6% from the August 31st total of 735,900 shares. Based on an average daily trading volume, of 169,700 shares, the short-interest ratio is presently 5.2 days. Currently, 3.0% of the company's stock are sold short.
View Medpace's Short Interest.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Medpace.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Sunday, October, 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.07 by $0.22. The firm had revenue of $295.57 million for the quarter, compared to the consensus estimate of $291.55 million. Medpace had a trailing twelve-month return on equity of 21.74% and a net margin of 17.07%. The firm's revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.13 EPS.
View Medpace's earnings history.

How has Medpace's stock been impacted by Coronavirus (COVID-19)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 154.7% and is now trading at $213.02.
View which stocks have been most impacted by COVID-19.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY21 earnings guidance on Monday, October, 25th. The company provided EPS guidance of $4.66-$4.77 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.78. The company issued revenue guidance of $1.135-$1.145 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for MEDP?

3 Wall Street analysts have issued 12 month price targets for Medpace's stock. Their forecasts range from $167.90 to $205.00. On average, they anticipate Medpace's stock price to reach $190.97 in the next twelve months. This suggests that the stock has a possible downside of 10.4%.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:

• August James Troendle, Chairman & Chief Executive Officer
• Jesse J. Geiger, President (LinkedIn Profile)
• Susan E. Burwig, Executive Vice President-Operations (LinkedIn Profile)
• Kevin M. Brady, Chief Financial Officer & Treasurer
• Daniel O’Leary, Senior Vice President-Medical Department

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

Some companies that are related to Medpace include Charles River Laboratories International (CRL), Bitcoin Group (BTGGF), PPD (PPD), Exact Sciences (EXAS), ICON Public (ICLR), Incyte (INCY), Syneos Health (SYNH), Anavex Life Sciences (AVXL), Absci (ABSI), National Research (NRC), Zymergen (ZY), Inotiv (NOTV), SomaLogic (SLGC), CM Life Sciences II (CMII) and Starpharma (SPHRY).
View all of MEDP's competitors.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (1.48%), Fisher Asset Management LLC (0.92%), Redwood Investments LLC (0.43%), Tributary Capital Management LLC (0.36%), Strs Ohio (0.30%) and Scout Investments Inc. (0.27%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Redwood Investments LLC, Scout Investments Inc., Dixon Hubard Feinour & Brown Inc. VA, Optimum Investment Advisors, Tributary Capital Management LLC, Virginia Retirement Systems ET AL, Hillsdale Investment Management Inc., and Exchange Traded Concepts LLC. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Fisher Asset Management LLC, Strs Ohio, Boston Trust Walden Corp, McGuire Investment Group LLC, New York State Teachers Retirement System, Private Advisor Group LLC, and YorkBridge Wealth Partners LLC. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $213.02.

How much money does Medpace make?

Medpace has a market capitalization of $7.63 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.00 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,600 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911 or via email at [email protected].